Pharmacokinetics, metabolite pro ling, safety, and tolerability of inhalation aerosol of 101bhg-d01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy chinese subjects

HIGHLIGHTS

• who: . and collaborators from the Gilead, United States Jiangsu University, China have published the paper: Pharmacokinetics, metabolite pro ling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects, in the Journal: (JOURNAL) of 21/Oct/2019
• what: The initial pharmacokinetics, metabolite profiling, safety and tolerability of 101BHG-D01 indicate that it is a good candidate for the treatment of COPD and enable further clinical development in subsequent studies in COPD patients.
• how: The authors conducted this study to evaluate the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.